MedTrace Logo

Amniotic Membrane in Total Knee Replacements to Reduce Scarring

NCT02088567 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2015-09-23

No results posted yet for this study

Summary

The overall objective of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in total knee replacement patients.

Conditions

  • Scarring

Interventions

PROCEDURE

Total Knee Arthroplasty

Total knee arthroplasty, per the usual practice of the physician.

OTHER

Application of dHACM

Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation

Sponsors & Collaborators

  • MiMedx Group, Inc.

    lead INDUSTRY

Principal Investigators

  • Maurice Jove, MD · Georgia Knee and Sports Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02088567 on ClinicalTrials.gov